Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Core Insights - Kyverna Therapeutics, Inc. is hosting a webcast event on August 28, 2025, to discuss its neuroimmunology franchise, focusing on KYV-101 and its potential applications in myasthenia gravis (MG) and stiff person syndrome (SPS) [1][2] Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, with its lead candidate, KYV-101, advancing through late-stage clinical development [4] - The company is conducting registrational trials for KYV-101 in MG and SPS, along with ongoing Phase 1/2 trials for lupus nephritis [4] - Kyverna is also exploring next-generation CAR T-cell therapies and has plans to expand into broader autoimmune indications with KYV-102, utilizing a proprietary whole blood rapid manufacturing process [4] Webcast Details - The webcast will feature presentations from the management team and renowned Key Opinion Leaders (KOLs), followed by a Q&A session [2][3] - The event aims to provide an in-depth look at KYV-101's differentiation and its potential for durable drug-free, disease-free remission, as well as a high-level overview of Kyverna's commercial strategy [6]